anti-CD3/anti-PSMA bispecific aptamer (Ixaka)

N/A

Report date: 2025/03/14 16:28:41
NME

Base Information

Drug Nameanti-CD3/anti-PSMA bispecific aptamer (Ixaka)
Drug Alias NamePSMAxCD3 bispecific aptamer (Ixaka)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide aptamer
Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsT cell surface glycoprotein CD3 modulators
TargetsProstate-Specific Membrane AntigenT cell surface glycoprotein CD3
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIxaka Ltd
China Registration ClassN/A

Develop Information

Active CompaniesAlaya.bio
Inactive CompaniesIxaka Ltd
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A